What patent does “Emblaveo” refer to?
“Emblaveo” is a brand name for the antibiotic combination aztreonam/avibactam. The term “Emblaveo patente” usually means the patent coverage for this product—who owns it, what it protects (the drug formulation, use, or manufacturing), and when that protection ends.
I can’t confirm the specific patent number or owner from the information provided here. If you share the patent number, country (e.g., US, EP, JP), or a link you saw, I can explain exactly what it covers and the expected timeline.
When does Emblaveo’s patent protection expire?
Patent expiry depends on jurisdiction and on what kind of protection you mean:
- primary patent term (typically 20 years from the earliest priority date, subject to adjustments)
- patent term extensions (where available)
- supplementary protection certificates (SPCs) in some regions
- exclusivity protections that are not “patents” (regulatory exclusivity)
To give an accurate date for Emblaveo, I need at least the jurisdiction (US/Europe/etc.) or the specific patent document.
Is Emblaveo protected by multiple patents or just one?
For branded medicines, patent portfolios often include more than one patent—for example, patents covering:
- specific compound(s) and compositions
- methods of using the drug (including particular indications or dosing)
- manufacturing processes
The “end of patent protection” for the market can be driven by the last-lingering relevant patent in the portfolio, not necessarily the first one filed.
Can generics or biosimilars launch before the patent expires?
For small-molecule antibiotics like aztreonam/avibactam, generic entry is usually blocked by unexpired relevant patents, unless a competitor challenges the patent (e.g., with an invalidity/non-infringement argument) or designs around the claims.
Whether entry is possible earlier also depends on any non-patent exclusivities granted by the regulator in that country.
How to check Emblaveo patents yourself (fast)
If you want to look it up, the usual route is:
- search by brand name “Emblaveo” in the national patent office database for your country/region, or
- use a global patent database with the drug’s generic name (aztreonam/avibactam) and key applicants.
If you tell me the country (or paste the patent link you found), I can map what that specific patent covers and interpret the likely impact on competition.
What I need from you to answer precisely
Reply with any one of the following:
1) the country/region (US, EP, UK, etc.), and the patent number (if you have it), or
2) a link/screenshot to the “Emblaveo patente” you saw, or
3) the company name listed on the patent page.
Then I can summarize: what the patent claims protect, its status, and the expected expiry/launch implications.